Acute myeloid leukemia with hepatic infiltration presenting as obstructive jaundice

Landis R. Walsh; Chaofan Yuan; James T. Boothe; Heather E. Conway; Andres E. Mindiola-Romero; Odeth O. Barrett-Campbell; Swaroopa Yerrabothala; Frederick Lansigan

doi:10.1016/j.lrr.2021.100251

Acute myeloid leukemia with hepatic infiltration presenting as obstructive jaundice

Landis R. Walsh, Chaofan Yuan, James T. Boothe, Heather E. Conway, Andres E. Mindiola-Romero, Odeth O. Barrett-Campbell, Swaroopa Yerrabothala, Frederick Lansigan

Research output: Contribution to journal › Article › peer-review

Abstract

We present the case of a 55-year-old woman who presented with laboratory studies concerning for acute myeloid leukemia (AML) as well as obstructive cholestasis. In similar previously reported cases, concerns of chemotherapy toxicity exacerbated by liver dysfunction or concerns of untreated, concurrent cholecystitis in a neutropenic patient often delay initiation of chemotherapy for full medical workup. At admission, our patient was started on the cytoreductive agent hydroxyurea. By day 10 of her medical workup, her liver function had improved with total bilirubin levels normalizing. At that time, full-dose 7 + 3 induction with cytarabine and daunorubicin was then initiated.

Original language	English (US)
Article number	100251
Journal	Leukemia Research Reports
Volume	15
DOIs	https://doi.org/10.1016/j.lrr.2021.100251
State	Published - Jan 2021
Externally published	Yes

Keywords

Acute myeloid leukemia
Chemotherapy
Cytoreductive therapy
Extramedullary manifestation of AML
Hydroxyurea

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.lrr.2021.100251

Cite this

@article{e274aab5b39c43a69b5dfa1a50ae3a7c,

title = "Acute myeloid leukemia with hepatic infiltration presenting as obstructive jaundice",

abstract = "We present the case of a 55-year-old woman who presented with laboratory studies concerning for acute myeloid leukemia (AML) as well as obstructive cholestasis. In similar previously reported cases, concerns of chemotherapy toxicity exacerbated by liver dysfunction or concerns of untreated, concurrent cholecystitis in a neutropenic patient often delay initiation of chemotherapy for full medical workup. At admission, our patient was started on the cytoreductive agent hydroxyurea. By day 10 of her medical workup, her liver function had improved with total bilirubin levels normalizing. At that time, full-dose 7 + 3 induction with cytarabine and daunorubicin was then initiated.",

keywords = "Acute myeloid leukemia, Chemotherapy, Cytoreductive therapy, Extramedullary manifestation of AML, Hydroxyurea",

author = "Walsh, {Landis R.} and Chaofan Yuan and Boothe, {James T.} and Conway, {Heather E.} and Mindiola-Romero, {Andres E.} and Barrett-Campbell, {Odeth O.} and Swaroopa Yerrabothala and Frederick Lansigan",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = jan,

doi = "10.1016/j.lrr.2021.100251",

language = "English (US)",

volume = "15",

journal = "Leukemia Research Reports",

issn = "2213-0489",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Acute myeloid leukemia with hepatic infiltration presenting as obstructive jaundice

AU - Walsh, Landis R.

AU - Yuan, Chaofan

AU - Boothe, James T.

AU - Conway, Heather E.

AU - Mindiola-Romero, Andres E.

AU - Barrett-Campbell, Odeth O.

AU - Yerrabothala, Swaroopa

AU - Lansigan, Frederick

PY - 2021/1

Y1 - 2021/1

N2 - We present the case of a 55-year-old woman who presented with laboratory studies concerning for acute myeloid leukemia (AML) as well as obstructive cholestasis. In similar previously reported cases, concerns of chemotherapy toxicity exacerbated by liver dysfunction or concerns of untreated, concurrent cholecystitis in a neutropenic patient often delay initiation of chemotherapy for full medical workup. At admission, our patient was started on the cytoreductive agent hydroxyurea. By day 10 of her medical workup, her liver function had improved with total bilirubin levels normalizing. At that time, full-dose 7 + 3 induction with cytarabine and daunorubicin was then initiated.

AB - We present the case of a 55-year-old woman who presented with laboratory studies concerning for acute myeloid leukemia (AML) as well as obstructive cholestasis. In similar previously reported cases, concerns of chemotherapy toxicity exacerbated by liver dysfunction or concerns of untreated, concurrent cholecystitis in a neutropenic patient often delay initiation of chemotherapy for full medical workup. At admission, our patient was started on the cytoreductive agent hydroxyurea. By day 10 of her medical workup, her liver function had improved with total bilirubin levels normalizing. At that time, full-dose 7 + 3 induction with cytarabine and daunorubicin was then initiated.

KW - Acute myeloid leukemia

KW - Chemotherapy

KW - Cytoreductive therapy

KW - Extramedullary manifestation of AML

KW - Hydroxyurea

UR - http://www.scopus.com/inward/record.url?scp=85107140861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107140861&partnerID=8YFLogxK

U2 - 10.1016/j.lrr.2021.100251

DO - 10.1016/j.lrr.2021.100251

M3 - Article

AN - SCOPUS:85107140861

SN - 2213-0489

VL - 15

JO - Leukemia Research Reports

JF - Leukemia Research Reports

M1 - 100251

ER -

Acute myeloid leukemia with hepatic infiltration presenting as obstructive jaundice

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this